Right Now
Aikido Pharma has developed DHA-dFdC, licensed From the University of Texas at Austin for the treatment of Pancreatic Cancer.Pancreatic cancer has the highest mortality rate of all major cancers. 91% of pancreatic cancer patients will die within five years of diagnosis – only 8% will survive more than five years. 74% of patients die within the first year of diagnosis.* Pancreatic cancer is one of the few cancers for which survival has not improved substantially over nearly 40 years.* For more information, visit us online or call us at 212-745-1373.
*Hirshberg Foundation for Pancreatic Cancer Research
- Home - AIkido Pharma Inc.
-
Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics
Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics
More Posts
Map
Aikido Pharma
Get DirectionsAikido Pharma
-
One Rockefeller Plaza
New York, New York 10020
United States - (212) 745-1373
Report This Post
Please complete the following requested information to flag this post and report abuse, or offensive content. Your report will be reviewed within 24 hours. We will take appropriate action as described in Findit terms of use.
